<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120366</url>
  </required_header>
  <id_info>
    <org_study_id>SURPRISE Study</org_study_id>
    <secondary_id>UMIN000002744</secondary_id>
    <nct_id>NCT01120366</nct_id>
  </id_info>
  <brief_title>Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation</brief_title>
  <acronym>SURPRISE</acronym>
  <official_title>Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SURPRISE Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SURPRISE Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the efficacy and safety of the humanized
      anti-human IL-6 receptor monoclonal antibody tocilizumab (TCZ) either in monotherapy or in
      combination therapy with methotrexate (MTX) in patients with an inadequate response to
      treatment with MTX.

      Furthermore, in patients who have been able to achieve control of disease activity via the
      above therapy, we investigate the possibility of stopping TCZ and verify safety when TCZ is
      restarted after disease recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we aim to prospectively and randomly evaluate efficacy for changes in clinical
      remission and joint destruction in RA patients in treatment with TCZ monotherapy(SWITCH) and
      in combination therapy with MTX(ADD-ON), and also to investigate the best therapeutic
      approach to achieve discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DAS28-ESR remission at 24 weeks</measure>
    <time_frame>at 24 week</time_frame>
    <description>Step 1: Investigation of the efficacy and safety of TCZ in combination therapy with MTX</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes over time in the number of patients maintaining discontinuation (maintenance rate)</measure>
    <time_frame>Week 52 to Week 104</time_frame>
    <description>Step 2: Investigation of discontinuation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in TSS score</measure>
    <time_frame>at 52 weeks (after treatment initiation)</time_frame>
    <description>Step 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of DAS28-ESR remission rate</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Step 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ACR response rate</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Step 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D scores over time</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Step 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>J-HAQ/HAQ scores over time</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Step 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDAI, CDAI, and Boolean remission rates</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Step 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α over time</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Step 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group comparison of the discontinuation rate after an achievement of remission</measure>
    <time_frame>Week 0 to Week 104</time_frame>
    <description>Step 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor analysis of patients maintaining discontinuation</measure>
    <time_frame>Week 0 to Week 104</time_frame>
    <description>Step 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of DAS28 after restarting TCZ (between-group comparison)</measure>
    <time_frame>Week 52 to Week 104</time_frame>
    <description>Step 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TSS score</measure>
    <time_frame>Week 52 to Week 104</time_frame>
    <description>Step 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of DAS28 after restarting MTX following suspension of discontinuation in the TCZ monotherapy group in Step 1</measure>
    <time_frame>Week 52 to Week 104</time_frame>
    <description>Step 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDAI, CDAI, and Boolean remission rates</measure>
    <time_frame>Week 52 to Week 104</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>During the study period</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SWITCH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tocilizumab monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADD-ON</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tocilizumab plus methotrexate combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab plus methotrexate</intervention_name>
    <description>Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.</description>
    <arm_group_label>ADD-ON</arm_group_label>
    <other_name>Actemra</other_name>
    <other_name>Methotrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.</description>
    <arm_group_label>SWITCH</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with RA in accordance with the 1987 classification criteria of ACR

          -  Aged 20 to 75 years inclusive at enrolment (within 2 weeks before starting treatment
             with the investigational drug)

          -  Treated with MTX at ≥6 mg/week for at least 8 weeks immediately before enrolment

          -  Rheumatoid arthritis of duration ≤10 years

          -  DAS28-ESR ≥3.2 (within 2 weeks before starting treatment with the investigational
             drug)

          -  Having received and thoroughly understood an adequate explanation about participation
             in the study, patients who have personally and voluntarily provided written informed
             consent

        Major exclusion criteria:

          -  Patients who were Steinbrocker Class IV.

          -  Patients who received leflunomide within 12 weeks, DMARDs other than MTX within 8
             weeks , or tacrolimus within 4 weeks before the 1st TCZ infusion.

          -  Patients who previously received biologic DMARDs including TCZ.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsutomu Takeuchi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keio University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hokkaido Medical Center for Rheumatic Diseases Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utazu Hama Clinic</name>
      <address>
        <city>Ayautagun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University</name>
      <address>
        <city>Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukushima Red-Cross Hospital</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashihiroshima Memorial Hospital</name>
      <address>
        <city>Higashihiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Dental College Ichikawa General Hospital</name>
      <address>
        <city>Ichikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Itabashi Medical Center</name>
      <address>
        <city>Itabashi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimane University Faculty of Medicine</name>
      <address>
        <city>Izumo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center, Saitama Medical University</name>
      <address>
        <city>Kawagoe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa University</name>
      <address>
        <city>Kida-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Occupational and Environmental Health Hospital</name>
      <address>
        <city>Kitakyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Sweet Hospital</name>
      <address>
        <city>Kurashiki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Graduate School of Medicine</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marunouchi Hospital</name>
      <address>
        <city>Matsumoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dogo Spa Hospital</name>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zenjinkai Shimin-no-mori Hospital</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Graduate School of Biomedical Sciences</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Graduate School of Medical and Dental Sciences</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oribe Rheumatism and Internal Medicine Clinic</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Graduate School of Medicine</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sasebo Chuo Hospital</name>
      <address>
        <city>Sasebo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Rheumatic Center</name>
      <address>
        <city>Shibata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology, Tokyo Women's Medical University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Graduate School of Medicine</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomishiro Chuo Hospital</name>
      <address>
        <city>Tomishiro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minami Kyousai Hospital</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <last_update_submitted>January 23, 2015</last_update_submitted>
  <last_update_submitted_qc>January 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

